Norgen Biotek Corp

Norgen Biotek Corp, a Canadian for-profit biotechnology manufacturer headquartered in Thorold, Ontario, supplies exosome purification kits, exosomal RNA extraction and isolation services, and small RNA sequencing support to the National Institutes of Health as a prime contractor on firm fixed-price purchase orders with no set-asides used across all recent awards. The vendor operates 100% as a prime (18 awards, all purchase orders) with no subcontract footprint and competes full-and-open, not under any SBA set-aside categories.

Norgen Biotek's customer concentration is extremely narrow and stable. The National Human Genome Research Institute accounts for 12 of 18 awards (67% of the portfolio by count) and $1.4 million of $1.5 million combined potential value (93% of dollars), with the remainder split across four other NIH institutes and the FDA. The vendor's award history spans back to 2010, but the recent five-year activity shows one to two awards per year — flat trajectory with no growth signal. The two awards completing in the next twenty-four months carry $44 thousand in combined potential value and represent the vendor's only near-term recompete exposure.

Representative work includes a $668,710 firm fixed-price purchase order from NHGRI (awarded May 2023) to extract and isolate intact RNA exosomes from plasma samples for a National Heart, Lung and Blood Institute clinical study; a $156,600 purchase order from NHGRI (September 2025) for small RNA characterization of urinary exosomes; and a $27,179 purchase order from the National Institute on Alcohol Abuse and Alcoholism (July 2026) for exosomal RNA purification, RNA quality control testing, and small RNA sequencing library preparation. NHGRI has awarded the vendor over $1 million in cumulative purchase orders since at least 2019, with individual contract values ranging from approximately $16,000 to $669,000. All identified work is performed either at Norgen Biotek's facilities in Ottawa, Ontario, or in Bethesda, Maryland (for services), with performance dates spanning completion through 2027.

Norgen Biotek is categorized under Testing Laboratories and Services and Research and Development in Biotechnology (4 awards each per NAICS coding), with primary PSC codes for Reference Laboratory Testing (5 awards) and Support–Professional (4 awards), reflecting the vendor's core role as a service laboratory rather than a product manufacturer in the federal portfolio.